tbuckley/cabot-search huggingface dataset:
Dimethyl Fumarate Ameliorates Graft-Versus-Host Disease By Negatively Regulating Aerobic Glycolysis in Alloreactive T-Cells
Authors: Kiyomi Mashima, Kazuya Sato, Norihito Takayama, Junko Izawa, Takashi Ikeda, Kento Umino, Hirofumi Nakano, Daisuke Minakata, Kaoru Morita, Chihiro Yamamoto, Masahiro Ashizawa, Kaoru Hatano, Iekuni Oh, Ken Ohmine, Shin-ichiro Fujiwara, Yoshinobu Kanda
Journal: Blood (2020)
CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas
Authors: Yang Cao, Yi Xiao, Na Wang, Gaoxiang Wang, Xiaoxi Zhou, Liang Huang, Liting Chen, Min Xiao, Tongcun Zhang, Yicheng Zhang, Jianfeng Zhou
Journal: Blood (2020)
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
Authors: Dan Sha, Zhaohui Jin, Jan Budczies, Klaus Kluck, Albrecht Stenzinger, Frank A. Sinicrope
Journal: Cancer Discovery (2020)

Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, varies across malignancies. Panel sequencing-based estimates of TMB have largely replaced whole-exome sequencing-derived TMB in the clinic. Retrospective evidence suggests that TMB can predict the efficacy of immune checkpoint inhibitors, and data from KEYNOTE-158 led to the recent FDA approval of pembrolizumab for the TMB-high tumor subgroup. Unmet needs include prospective validation of TMB cutoffs in relationship to tumor type and patient outcomes. Furthermore, standardization and harmonization of TMB measurement across test platforms are important to the successful implementation of TMB in clinical practice. SIGNIFICANCE: Evaluation of TMB as a predictive biomarker creates the need to harmonize panel-based TMB estimation and standardize its reporting. TMB can improve the predictive accuracy for immunotherapy outcomes, and has the potential to expand the candidate pool of patients for treatment with immune checkpoint inhibitors.
Cardiac Morbidity in Adolescents and Young Adult Survivors of Hodgkin Lymphoma
Authors: Kristin C. Marr, Jonathan Simkin, Andrea C. Lo, Joseph M. Connors, Alina S. Gerrie, Diego Villa, Ciara L. Freeman, David W. Scott, Greg Hapgood, Laurie H. Sehn, Ryan Woods, Kerry J. Savage
Journal: Blood (2020)
Antibody Response Against Sars-Cov-2 in Convalescent Plasma Donors: Preliminary Results from a Single Center in Midwest Brazil
Authors: Maria do Rosario Ferraz Roberti, Tiago Paiva Prudente, Renato Gomes Castro, Marcos Antonio Candido, Roberta Luiza Rodrigues, Francielle Barreto Machado Candido, Alexandra Vilela Gonçalves, Jaciane Soares de Sá, Marcelo Fouad Rabahi, Adriano de Moraes Arantes
Journal: Blood (2020)
Kidney epithelial targeted mitochondrial transcription factor A deficiency results in progressive mitochondrial depletion associated with severe cystic disease
Authors: Ken Ishii, Hanako Kobayashi, Kensei Taguchi, Nan Guan, Andraia Li, Carmen Tong, Olena Davidoff, Pamela V. Tran, Madhulika Sharma, Navdeep S. Chandel, Meghan E. Kapp, Agnes B. Fogo, Craig R. Brooks, Volker H. Haase
Journal: Kidney International (2020)
Hodgkin Variant of Richter's Transformation (HvRT) Among Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC), Canada
Authors: Kai Zhu, Andrew Jamroz, Steven J.T. Huang, Diego Villa, Ciara L. Freeman, David W. Scott, Graham W. Slack, Laurie H. Sehn, Joseph M. Connors, Cynthia L. Toze, Kerry J. Savage, Alina S. Gerrie
Journal: Blood (2020)
Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data
Authors: Reyka G Jayasinghe, Lijun Yao, Beena Thomas, Swati S Bhasin, Nicolas Fernandez, David E. Avigan, Taxiarchis Kourelis, Madhav V. Dhodapkar, Ravi Vij, Shaadi Mehr, Mark Hamilton, Hearn Jay Cho, Daniel Auclair, Sacha Gnjatic, Li Ding
Journal: Blood (2020)
Clinical Characteristics and Risk Factors for Adverse Outcomes of Influenza Infections in Hematopoietic Stem Cell Transplant Recipients
Authors: Brian J. Chernak, Emily Coskun, Nina Orfali, Yuqing Qiu, Rosemary Soave, Tsiporah B. Shore, Koen van Besien, Mirella Salvatore
Journal: Blood (2020)
Exercise interventions in lateral elbow tendinopathy have better outcomes than passive interventions, but the effects are small: a systematic review and meta-analysis of 2123 subjects in 30 trials
Authors: Stefanos Karanasios, Vasileios Korakakis, Rod Whiteley, Ioannis Vasilogeorgis, Sarah Woodbridge, Georgios Gioftsos
Journal: British Journal of Sports Medicine (2020)

Objective To evaluate the effectiveness of exercise compared with other conservative interventions in the management of lateral elbow tendinopathy (LET) on pain and function. Design Systematic review and meta-analysis. Methods We used the Cochrane risk-of-bias tool 2 for randomised controlled trials (RCTs) to assess risk of bias and the Grading of Recommendations Assessment, Development and Evaluation methodology to grade the certainty of evidence. Self-perceived improvement, pain intensity, pain-free grip strength (PFGS) and elbow disability were used as primary outcome measures. Eligibility criteria RCTs assessing the effectiveness of exercise alone or as an additive intervention compared with passive interventions, wait-and-see or injections in patients with LET. Results 30 RCTs (2123 participants, 5 comparator interventions) were identified. Exercise outperformed (low certainty) corticosteroid injections in all outcomes at all time points except short-term pain reduction. Clinically significant differences were found in PFGS at short-term (mean difference (MD): 12.15, (95% CI) 1.69 to 22.6), mid-term (MD: 22.45, 95% CI 3.63 to 41.3) and long-term follow-up (MD: 18, 95% CI 11.17 to 24.84). Statistically significant differences (very low certainty) for exercise compared with wait-and-see were found only in self-perceived improvement at short-term, pain reduction and elbow disability at short-term and long-term follow-up. Substantial heterogeneity in descriptions of equipment, load, duration and frequency of exercise programmes were evident. Conclusions Low and very low certainty evidence suggests exercise is effective compared with passive interventions with or without invasive treatment in LET, but the effect is small. PROSPERO registration number CRD42018082703.
Efficacy and Safety of Ixazomib Induction and Maintenance in Newly Diagnosed Multiple Myeloma Patients According to the IMWG Frailty Score: A Post-Hoc Analysis of the EMN10-Unito Trial
Authors: Roberto Mina, Alessandra Larocca, Massimo Offidani, Vanessa Innao, Claudia Cellini, Monica Galli, Giusy Cetani, Mariella Grasso, Giovannino Ciccone, Andrea Capra, Sara Aquino, Claudia Priola, Gloria Margiotta Casaluci, Giovanni De Sabbata, Stelvio Ballanti, Michele Cavo, Mario Boccadoro, Sara Bringhen
Journal: Blood (2020)
Comparative Effectiveness of Bendamustine Plus Rituximab (BR) and Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Authors: Felipe Castro, Andy Surinach, Aino Launonen, Per-Olof Thuresson, Federico Felizzi
Journal: Blood (2020)
A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
Authors: Rafael Bejar, Hongying Zhang, Nasrin Rastgoo, Khalid Benbatoul, Yuying Jin, Matthew Thayer, Susan Sheng, Gregory k Chow, Victor Montalvo-Lugo, Jotin Marango, Stephen B Howell, William G Rice
Journal: Blood (2020)
Pharmacokinetics/Pharmacodynamics, Safety and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease and a History of Vaso-Occlusive Crises: Results from the Phase II, Multicenter, Open-Label Solace-Adults Study
Authors: Darla Liles, Kim Smith-Whitley, R Clark Brown, Nirmish Shah, Santosh M Nair, Chiaki Tanaka, Shankaranand Bodla, Gessami Sanchez-Olle, Urs Albers, Julie Kanter
Journal: Blood (2020)
Biological Impact of Monoallelic and Biallelic <i>BIRC3</i> Loss in Del(11q) Chronic Lymphocytic Leukemia Progression
Authors: Miguel Quijada Álamo, Maria Hernandez-Sanchez, Ana E. Rodriguez, Claudia Pérez Carretero, Marta Martín Izquierdo, Verónica Alonso Pérez, Ignacio García-Tuñón, Jose Maria Bastida, Maria Jesus Vidal, Josefina Galende DEL Canto, Carlos Aguilar, José Antonio Queizán, Isabel González-Gascón Y Marín, Jose-Angel Hernandez, Rocio Benito, José Luis Ordóñez, Jesus Maria Hernández-Rivas
Journal: Blood (2020)
Ker-050, a Novel Inhibitor of Tgfβ Superfamily Signaling, Induces Red Blood Cell Production By Promoting Multiple Stages of Erythroid Differentiation
Authors: Marina Feigenson, Remya Nathan, Christopher Materna, Alana Gudelsky, Evan Lema, Claire C Tseng, Ffolliott Fisher, Jasbir Seehra, Jenn Lachey
Journal: Blood (2020)
A Disease of Parrots Communicable to Man (Psittacosis).
Authors: E. L. Sturdee, W. M. Scott
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis
Authors: Imad M. Tleyjeh, Zakariya Kashour, Moussab Damlaj, Muhammad Riaz, Haytham Tlayjeh, Mustafa Altannir, Youssef Altannir, Mohamad Al-Tannir, Rana Tleyjeh, Leslie Hassett, Tarek Kashour
Journal: Clinical Microbiology and Infection (2020)
Re: effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: author's response
Authors: Thibault Fiolet, Anthony Guihur, Mathieu Edouard Rebeaud, Matthieu Mulot, Nathan Peiffer-Smadja, Yahya Mahamat-Saleh
Journal: Clinical Microbiology and Infection (2020)
Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia
Authors: Caroline Duault, Anil Kumar, Adeleh Taghi Khani, Sung June Lee, Lu Yang, Min Huang, Christian Hurtz, Bryan Manning, Lucy Ghoda, Tinisha McDonald, Norman J. Lacayo, Kathleen M. Sakamoto, Martin P. Carroll, Guido Marcucci, Jianhua Yu, Michael A. Caligiuri, Holden T. Maecker, Srividya Swaminathan
Journal: Blood (2020)
Mir-125b Regulates the Self-Renewal of Acute Myeloid Leukemia Stem Cells through PTPN18 and GSK3
Authors: Qiang Liu, Olga I. Gan, Gabriela Krivdova, Aaron Trotman-Grant, Stephanie M. Dobson, Karin G. Hermans, Mark D. Minden, Shai Izraeli, John E. Dick, Jean C.Y. Wang, Eric R. Lechman,
Journal: Blood (2020)
FRI0266 THE REAL-WORLD EFFICACY OF THE 2015 EULAR/ACR RECOMMENDATIONS FOR THE MANAGEMENT OF POLYMYALGIA RHEUMATICA WITH ADDITIONAL TOCILIZUMAB THERAPY
Authors: M. Yamamura
Journal: Annals of the Rheumatic Diseases (2020)

Background: A Part of patients with polymyalgia rheumatica (PMR) are refractory to the 2015 EULAR/ACR algorism for the management of PMR. Recent reports have demonstrated that tocilizumab (TCZ) may be efficacious for refractory and relapsing PMR. Objectives: To determine the real-world efficacy of the 2015 EULAR/ACR algorism for the management of PMR plus introduction of TCZ for refractory and relapsing PMR. Methods: Patients who had been diagnosed with PMR according to the 2012 EULAR/ACR provisional classification criteria for PMR were recruited in the study. Registered variables included demographic data, disease characteristics, prednisolone (PSL) dosage and duration, addition of methotrexate (MTX) and TCZ, adverse effects, and clinical outcomes. Results: There were 101 patients who had originally diagnosed as PMR (50 males and 65 females) and followed up for at least one year; the mean ± SD age at onset was 73 ±11 years at onset, with the mean observational period being 44 ± 26 months. Their treatments were initiated with PSL of 15.5 ± 4.3 mg/day. 41 patients experienced disease recurrence after 9.6 ± 6.7 months (median 9 month) of GC therapy, while receiving PSL at 5 ± 4.5 mg/day (3.7 mg/day). Baseline factors that were associated with relapse in our cohort were higher-grade thrombocytosis and higher-dose of initial GC by multivariate analysis. In 30 of the 41 patients who failed GC monotherapy, MTX was added. Five patients reached GC-free remission, but 25 patients failed GC tapering. In such refractory patients to a combination of GC plus MTX, 8 patients agreed to add TCZ therapy, and 5 of them reached drug-free remission. At present, 67 of the total 101 patients maintained drug-free remission, but most others were still receiving low-dose GC and/or MTX (n=17). No significant adverse effects did not occur during therapy, except for GC-related adverse effects such as diabetes, dyslipidemia and osteoprotic fractures. Conclusion: Our experience indicated that there is notable heterogeneity across PMR patients in terms of drug response, and the patients with severe inflammation, e.g. thrombocytosis, may need higher-dose of initial GC and addition of biologics such as TCZ on the 2015 EULAR/ACR algorism. Acknowledgments: None Disclosure of Interests: None declared
Impact of Novel Therapies on CD4-T-Cell-Numbers and Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Lukas John, Kaya Miah, Axel Benner, Elias K Mai, Katharina Kriegsmann, Michael Hundemer, Carsten Mueller-Tidow, Karin Jordan, Hartmut Goldschmidt, Marc S. Raab, Nicola Giesen
Journal: Blood (2020)
Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents
Authors: Anna Eversman, Shufen Cao, Kirsten M Boughan, Molly M Gallogly, Ehsan Malek, Leland Metheny, Timothy E. O'Brien, Folashade Otegbeye, Brenda W. Cooper, Pingfu Fu, Marcos de Lima, Paolo F Caimi
Journal: Blood (2020)
How Many Patients Have Congenital Neutropenia? a Population-Based Estimation from the Nationwide French Severe Chronic Neutropenia Registry
Authors: Jean Donadieu, Blandine Beaupain, Hélène Lapillonne, Odile Fenneteau, Flore Sicre de Fontbrune, Yves Bertrand, Nathalie Aladjidi, Vincent Barlogis, Wadih Abou Chahla, Thierry Lamy, Aline Moignet Autrel, Claire Fieschi, Thierry Leblanc, Despina Moshous, Jean Soulier, Sarah cohen Beaussant, Francois Delhommeau, Helene Cavé, Catherine Paillard, Elodie Gouache, Fares bou Mitri, Damien Bonnet, Laurence Olivier Faivre, Philippe Labrune, Marlène Pasquet, Virginie Gandemer, Nizar Mahlaoui, Karl Balabanian, Francoise Bachelerie, Christine Bellanne-Chantelot
Journal: Blood (2020)
DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses
Authors: Ewa Cendrowicz, Lisa Jacob, Shirley Greenwald, Ami Tamir, Yosi Gozlan, Gerwin Huls, Adam Foley-Comer, Yaron Pereg, Ayelet Chajut, Amnon Peled, Edwin Bremer
Journal: Blood (2020)
Trichodysplasia Spinulosa in a Kidney Transplant Recipient
Authors: Anna Sonstegard, Marc Grossman, Amit Garg
Journal: JAMA Dermatology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Phase 1 Trial of Prophylactic Donor-Derived IL-2 Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor
Authors: Raynier Devillier, Boris Calmels, Sophie Guia, Cyril Fauriat, Sabine Furst, Samia Harbi, Angela Granata, Sophie Ugolini, Christian Chabannon, Daniel Olive, Eric Vivier, Didier Blaise
Journal: Blood (2020)
A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
Authors: Raija Helena Silvennoinen, Anders Waage, Valdas Peceliunas, Fredrik Schjesvold, Pekka Anttila, Marjaana Säily, Mervi Putkonen, Kristina Carlson, Einar Haukaas, Marja Sankelo, Anu Partanen, Damian L. Szatkowski, Markus Hansson, Anu Marttila, Lucia Ahlberg, Per Axelsson, Birgitta Lauri, Maija Helena Mikkola, Conny Karlsson, Johanna Abelsson, Erik Ahlstrand, Anu Sikiö, Monika Klimkowska, Reda Matuzeviciene, Mona Hoysaeter Fenstad, Sorella Ilveskero, Hareth Nahi
Journal: Blood (2020)
CD34+ Positive Myelodysplastic Cells with Ring Sideroblasts or SF3B1 Mutation Produce High Erythroferrone and GDF15
Authors: Hiroto Horiguchi, Masayoshi Kobune, Kento Ono, Saori Shimoyama, Chisa Fujita, Akari Goto, Hiroshi Ikeda, Satoshi Iyama
Journal: Blood (2020)
Myocardial Injury in Adults Hospitalized With COVID-19
Authors: Nathaniel R. Smilowitz, Neil Jethani, Ji Chen, Yindalon Aphinyanaphongs, Ruina Zhang, Siddhant Dogra, Carlos L. Alviar, Norma Keller, Louai Razzouk, Adriana Quinones-Camacho, Albert S. Jung, Glenn I. Fishman, Judith S. Hochman, Jeffrey S. Berger
Journal: Circulation (2020)

][3] Myocardial injury, defined by elevated cardiac troponin (cTn) concentrations, is common in critical illness and has been reported during hospitalization in up to 36% of COVID-19 hospitalizations. 1,4We explored the frequency of myocardial injury at admission and during hospitalization and evaluated associations between myocardial injury and clinical outcomes in a large cohort of patients with CO-VID-19 from a high-volume health care system in New York.The study was approved by the New York University School of Medicine Institutional Review Board with a waiver of informed consent.Identifiable data will not be made available to the public.We identified consecutive adults age ≥18 years with confirmed SARS CoV-2 infection admitted to the New York University Langone Health system between March 1, 2020 and April 16, 2020.Patients were eligible for inclusion if ≥1 cTn was measured during hospitalization.Routine cTn surveillance was performed in 95% of COVID-19 admissions because cTn assays were included in COVID-19-specific order sets in the electronic heath record.Non-high-sensitivity cTn assays were used (Siemens Dimension Vista Troponin I, Washington DC; Abbot Architect Troponin I, Chicago, IL).The initial and maximum cTnI measured during hospital admission were recorded.Myocardial injury was defined as cTn >99% upper reference limit for the cTn assay.Individuals were stratified into tertiles by initial and maximum cTn concentrations normalized to the assay-specific limit of detection.All-cause, in-hospital mortality was recorded for all patients.Critical illness was defined by treatment in an intensive care unit, need for mechanical ventilation, discharge to hospice, or death.Patient characteristics, laboratory data, and clinical outcomes were ascertained via automated extraction from the electronic health record.Categorical variables were compared by χ 2 tests, and continuous variables were compared using Mann-Whitney tests.Logistic regression models were generated to estimate the odds of the study end points, adjusted for demographics, comorbidities, vital signs, laboratory findings, and baseline medications.Statistical tests are 2-sided, and P values <0.05 were considered statistically significant.A total of 2163 consecutive adults with COVID-19 and ≥1 cTn measurement were identified.Myocardial injury was present at the initial cTn measurement in 665 (30.7%) cases.Patients with myocardial injury were older (71 versus 61 years; P<0.001) and more likely to be male (67.1% versus 61.5%; P=0.016).In-hospital mortality was higher in patients with myocardial injury at initial cTn measurement compared with those without myocardial injury (37.0%versus 15.4%; P<0.001; adjusted odds ratio [aOR], 2.04 [95% CI, 1.52-2.82]).Critical illness (54.1% versus 28.9%; P<0.001; aOR, 1.67 [95% CI, 1.23-2.07])was
Clinical Response Evaluation Toward Individualizing the Starting Dose of Dasatinib in Asian Patients with Chronic Myeloid Leukemia
Authors: Hyejin Shin, Jung-Eun Ha, Dae Young Zang, Sung-Hyun Kim, Young Rok Do, Won Sik Lee, Soo-Hyun Kim, Kyung-Mi Kee, Seon-Young Yang, So-Yoon Hwang, Eun-Jung Jang, Jangik Lee, Dong-Wook Kim
Journal: Blood (2020)
SARS-CoV-2 infection: the environmental endurance of the virus can be influenced by the increase of temperature
Authors: Fabio Magurano, Melissa Baggieri, Antonella Marchi, Giovanni Rezza, Loredana Nicoletti, Benedetti Eleonora, Fabiani Concetta, Fiore Stefano, Kojouri Maedeh, Bucci Paola, D'Ugo Emilio, Gioacchini Silvia
Journal: Clinical Microbiology and Infection (2020)

ObjectivesTo evaluate whether the increase of temperature can influence the environmental endurance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).MethodsVirus was inoculated on a plastic surface and harvested at predefined time-points in parallel at 20°C–25°C (room temperature; RT) and at 28°C (June temperature; JT). Samples were tested by TCID50 titres on Vero cells.ResultsOur results confirm that fomite transmission of the emerging SARS-CoV-2 is possible: the virus reserved its ability to infect cells for up to 84 hours at both RT and JT on a plastic surface, with TCID50 viral titres of 0.67 and 0.25 log10, respectively. At RT, an important reduction in the viral titre, from 4 log10 to 3 log10 TCID50, was observed during the first 24–36 hours. At JT, the same decay was observed more rapidly (between 8 and 12 hours), The rate of viral inactivation by D-value was 24.74 hours at RT and 12.21 hours at JT.ConclusionsThis remarkable difference between the two temperatures suggests that virus vitality can be influenced by the environmental temperature and that the hot season could reduce the probability of COVID-19 transmission.
Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma
Authors: Jean-Marie Michot, Reda Bouabdallah, Jeanette K. Doorduijn, Carola Boccomini, Marie José Kersten, Annalisa Chiappella, Pier Luigi Zinzani, Gilles Salles, Fontanet Bijou, Mei Hentrup, So Hyun Rhee, Patrick Hagner, Christian Klein, Michael Pourdehnad, Kristen Hege, Juergen Dobmeyer, Zariana Nikolova, Vincent Ribrag
Journal: Blood (2020)
Population Pharmacokinetic/Pharmacodynamic Modelling from the Phase I/II COMPOSER Trial to Predict Lowering of Lactate Dehydrogenase in Crovalimab-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria
Authors: Simon Buatois, Alexandre Sostelly, Antoine Soubret, Felix Jaminion, Valerie Cosson
Journal: Blood (2020)